THX Pharma Announces June 2026 Cash Position

THX Pharma, a biopharmaceutical company in Lyon, has reported a cash position of €17.5 million as of June 30, 2026, down from €19.9 million at the end of March. This reduction reflects the company's roadmap execution, with an active Phase 3 study for Batten disease. This study is fully funded by Biocodex, securing THX Pharma's financial outlook.

CEO Mathieu Charvériat highlighted significant milestones in early 2026, including a positive opinion from the EMA's Paediatric Committee for TX01. This approval secures ten years of protection in Europe for Niemann-Pick disease type C. Additionally, Allinvest Securities initiated coverage of THX Pharma stock with a Buy recommendation and a target price of €10.4 per share.